Skip to main content
Use of the Tidepool Platform to Collect, Integrate, and Visualize Diabetes Device Data in a Pediatric Clinic Setting.
Impact of Target HbA1c Change in Pediatric Participants in the T1D Exchange Clinic Registry.
Clinical Practice Factors That Define Insulin Pump Readiness.
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Recommendations for the definition of clinical responder in insulin preservation studies.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Immune therapy and ß-cell death in type 1 diabetes.
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function.
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Through the fog: recent clinical trials to preserve ß-cell function in type 1 diabetes.